Table 1 Studies reporting discontinuation of biologics due to loss of efficacy or adverse effects.
From: Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence
References | Patient papulation | Drug survival rate | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 year | 2 years | 3 years | 4 years | 5 years | 6 years | 10 years | |||||||||
n | % | n | % | n | % | n | % | n | % | n | % | n | % | ||
Loss of efficacy | |||||||||||||||
Etanercept | |||||||||||||||
Zweegers et al.36 | 238 | 193 | 81.1 | 161 | 67.6 | 148 | 62.2 | 122 | 51.4 | 107 | 45 | — | — | 74 | 31 |
Vilarrasa et al.34 | 248 | 192 | 77.6 | 142 | 57.1 | 116 | 46.9 | 101 | 40.8 | — | — | — | — | — | — |
Warren et al.35 | 1098 | 878 | 80 | 714 | 65 | 604 | 55 | — | — | — | — | — | — | — | — |
Van den Reek et al.31 | 82 | 68 | 83 | — | — | — | — | — | — | — | — | — | — | — | — |
Davila-Seijo et al.13 | 672 | 543 | 80.8 | 439 | 65.4 | 362 | 53.9 | 336 | 50.0 | ||||||
Adalimumab | |||||||||||||||
Zweegers et al.36 | 186 | 161 | 86.5 | 136 | 73.0 | 121 | 64.9 | 116 | 62.2 | 100 | 54 | 93 | 50 | ||
Vilarrasa et al.34 | 231 | 188 | 81.6 | 155 | 67.3 | 141 | 61.2 | 118 | 51 | — | — | — | — | — | — |
Van den Reek et al.41 | 459 | — | — | — | — | — | — | 285 | 62 | — | — | — | — | — | — |
Warren et al.35 | 1879 | 1691 | 90 | 1560 | 83 | 1484 | 79 | — | — | — | — | — | — | — | — |
Van den Reek et al.31 | 101 | 86 | 85 | — | — | — | — | — | — | — | — | — | — | — | — |
Davila-Seijo et al.13 | 724 | 696 | 96.2 | 487 | 67.3 | 446 | 61.5 | 390 | 53.9 | ||||||
Infliximab | |||||||||||||||
Vilarrasa et al.34 | 84 | 67 | 79.6 | 55 | 65.3 | 48 | 57.1 | 41 | 49 | — | — | — | — | — | — |
Warren et al.35 | 96 | 83 | 86 | 76 | 79 | 73 | 76 | — | — | — | — | — | — | — | — |
Davila-Seijo et al.13 | 188 | 181 | 96.2 | 130 | 69.2 | 108 | 57.7 | 101 | 53.9 | ||||||
Ustekinumab | |||||||||||||||
Zweegers et al.36 | 102 | 94 | 91.9 | 88 | 86.5 | 88 | 86.5 | 85 | 83.8 | 81 | 79 | — | — | — | — |
Vilarrasa et al.34 | 140 | 131 | 93.8 | 131 | 93.8 | 120 | 85.7 | 114 | 81.6 | — | — | — | — | — | — |
Warren et al.35 | 450 | 432 | 96 | 419 | 93 | 401 | 89 | — | — | — | — | — | — | — | — |
Van den Reek et al.31 | 66 | 62 | 94 | — | — | — | — | — | — | — | — | — | — | — | — |
Davila-Seijo et al.13 | 491 | 444 | 90.4 | 415 | 84.6 | 378 | 76.9 | 359 | 73.1 | ||||||
Adverse effects | |||||||||||||||
Etanercept | |||||||||||||||
Zweegers et al.36 | 238 | 228 | 95.9 | 212 | 89.2 | 212 | 89.2 | 212 | 89.2 | — | — | — | — | 167 | 70 |
Warren et al.35 | 1098 | 1032 | 94.0 | 999 | 91.0 | 988 | 90.0 | — | — | — | — | — | — | — | — |
Van den Reek et al.31 | 82 | 74 | 90.0 | — | — | — | — | — | — | — | — | — | — | — | — |
Davila-Seijo et al.13 | 672 | 620 | 92.3 | 594 | 88.5 | 569 | 84.6 | 597 | 88.8 | ||||||
Adalimumab | |||||||||||||||
Zweegers et al.36 | 186 | 166 | 89.2 | 156 | 83.8 | 153 | 82.4 | 151 | 81.1 | — | — | 130 | 70 | — | — |
Van den Reek41 | 459 | — | — | — | — | — | — | 386 | 84.0 | — | — | — | — | — | — |
Warren et al.35 | 1879 | 1747 | 93.0 | 1681 | 90.0 | 1635 | 87 | — | — | — | — | — | — | — | — |
Van den Reek et al.31 | 101 | 96 | 95.0 | — | — | — | — | — | — | — | — | — | — | — | — |
Davila-Seijo et al.13 | 724 | 668 | 92.3 | 640 | 88.5 | 640 | 88.5 | 613 | 84.6 | ||||||
Infliximab | |||||||||||||||
Warren et al.35 | 96 | 81 | 84.0 | 71 | 74.0 | 57 | 59.0 | — | — | — | — | — | — | — | — |
Davila-Seijo et al.13 | 188 | 159 | 84.6 | 152 | 80.8 | 145 | 76.9 | 137 | 73.1 | ||||||
Ustekinumab | |||||||||||||||
Zweegers et al.36 | 102 | 94 | 91.9 | 85 | 83.8 | 85 | 83.8 | 77 | 75.7 | ||||||
Warren et al.35 | 450 | 432 | 96.0 | 419 | 93.0 | 410 | 91.0 | — | — | — | — | — | — | — | — |
Van den Reek et al.31 | 66 | 63 | 95.0 | — | — | — | — | — | — | — | — | — | — | — | — |
Davila-Seijo et al.13 | 491 | 491 | 100.0 | 472 | 96.2 | 472 | 96.2 | 472 | 96.2 | ||||||
